Phenolic antioxidants: a rationale for design and evaluation of novel antioxidant drug for atherosclerosis.
With increasing evidence that shows the involvement of active oxygen and nitrogen species in a variety of disorders, cancer, and aging, the role of antioxidant against oxidative stress has received renewed attention. In this review article, a rationale for design of lipophilic, radical-scavenging antioxidant is presented and the potency of a novel antioxidant, 2,3-dihydro-5-hydroxy-2,2-dipentyl-4, 6-di-tert-butylbenzofuran (BO-653), as an inhibitor of LDL oxidation was evaluated by considering various factors such as reactivity toward radicals, localization, and mobility in the lipoprotein, and fate of its radical. The anti-atherogenic activity of BO-653 was compared with those of alpha-tocopherol, probucol, and its metabolites. Furthermore, a novel function of phenolic antioxidants such as cell regulation and induction of phase II defense antioxidants are also discussed.
University of Tokyo, Research Center for Advanced Science and Technology, Komaba, Meguro, Tokyo, Japan.
N
N
Noguchi
E
E
Niki
D000818:Animals; D000975:Antioxidants / Q000737:chemistry / Q000494:pharmacology*; D001161:Arteriosclerosis / Q000188:drug therapy* / Q000378:metabolism / Q000517:prevention & control; D001572:Benzofurans / Q000737:chemistry / Q000494:pharmacology*; D015195:Drug Design; D004355:Drug Stability; D016166:Free Radical Scavengers / Q000494:pharmacology; D006801:Humans; D014810:Vitamin E / Q000494:pharmacology
C106512:2,3-dihydro-5-hydroxy-2,2-dipentyl-4,6-di-tert-butylbenzofuran; D000975:Antioxidants; D001572:Benzofurans; D016166:Free Radical Scavengers; D014810:Vitamin E